Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06335069

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.

Sponsor: Maastricht University Medical Center

Conditions Breast Cancer Breast Diseases Breast Neoplasms

Interventions 68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI

Updated 4 times since 2024 Last updated: Sep 19, 2025 Started: Sep 1, 2025 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06335069, this PHASE2 trial focuses on Breast Cancer and Breast Diseases and remains actively recruiting participants. Sponsored by Maastricht University Medical Center, it has been updated 4 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maastricht University Medical Center

Data source: Maastricht University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maastricht, Netherlands